By Jamal Bouie and Niranjan Aryal. A review of the literature to examine the analgesic properties of cannabis.
What changes need to be adopted in our industry to make the transition to the pharmaceutical industry testing paradigm?
GW Pharmaceuticals recently announced the company’s financial results from the second quarter of 2019.
Big Pharma is working on locking up cannabis patents, creating partnerships, and standing by to use its financial muscle for more ownership of the medical cannabis industry when the time is right.
Beyond Delta-9-THC and CBD: Current Evidence for Medical Benefit of Terpenes and Less Studied Cannabinoids
Lesser known cannabinoids and terpenes may be helpful for patients. Here the author shows why, and how patients can choose more effective medical cannabis products.
By A.C. Braddock and Amber Wise. By understanding whole-plant extractions better, businesses will be able to better plan for long-term profitability and sustainability.
David L. Nathan, MD, DFAPA, President, Board of Directors, Doctors for Cannabis Regulations (DFCR), discusses how the DFCR was formed, the efforts they have been making in the cannabis field, and plans for the future of the organization.
In honor of National Women’s Month, Josh Crossney highlights some of the amazing women that will be speaking at the first Cannabis Science Conference East show.
Ricki Lake discusses returning to Baltimore to speak at CSC East and her award-winning documentary, Weed the People.
Here we take a closer look at Australia’s medical cannabis program, the laws surrounding it, and speak to Australian pharmacist Paul Mavor.